

## Outcomes Measures Data Entry Walkthrough

### Step 1

On the Results Section page, click on the **Open** link next to Outcome Measures.

**Results Section**

[Record Summary](#) [Preview Results](#) [Download Results XML](#) [Delete Results](#) [Help](#) [Definitions](#)

[Open](#) **Participant Flow**

Pre-assignment Details  
Of 205 enrolled participants, 200 met inclusion criteria and were randomized to treatment.  
  
Trial Period: Overall Study Total Started: 200 [Protocol Enrollment: 205]

[Open](#) **Baseline Characteristics**

Overall Number of Baseline Participants: 200  
Age, Continuous  
Sex: Female, Male  
Ethnicity (NIH/OMB)  
Race (NIH/OMB)  
Region of Enrollment  
Quebec Task Force Classification of Spinal Disorders [Study-Specific Measure]  
Body Mass Index [Study-Specific Measure]  
Short Pain Scale (SPS-11) Score [Study-Specific Measure]  
Duration of Disc Herniation [Study-Specific Measure]  
Height [Study-Specific Measure]  
Weight [Study-Specific Measure]

[Open](#) **Outcome Measures**

1

Primary Outcome Measure(s):  
1. Data Not Reported Change From Baseline in Pain on the 11-point Short Pain Scale (SPS-11) at Week 24 [Time Frame: Baseline and Week 24]  
If reporting a score on a scale, please include the unabbreviated scale title, the minimum and maximum values, and whether higher scores mean a better or worse outcome.  
  
Secondary Outcome Measure(s):  
2. Data Not Reported Response Rate - 50 Percent or Greater Reduction in Short Pain Scale (SPS-11) Score [Time Frame: 12 weeks]  
If reporting a score on a scale, please include the unabbreviated scale title, the minimum and maximum values, and whether higher scores mean a better or worse outcome.  
3. Data Not Reported Response Rate - 50 Percent or Greater Reduction in Short Pain Scale (SPS-11) Score [Time Frame: 24 weeks]  
If reporting a score on a scale, please include the unabbreviated scale title, the minimum and maximum values, and whether higher scores mean a better or worse outcome.  
4. Data Not Reported Response Rate - 75 Percent or Greater Reduction in Short Pain Scale (SPS-11) Score [Time Frame: 24 weeks]  
If reporting a score on a scale, please include the unabbreviated scale title, the minimum and maximum values, and whether higher scores mean a better or worse outcome.  
  
Information is required

[Edit](#) **Adverse Events**

Information is required

### Step 2

The images for steps 2–12 show entry of continuous data for the primary outcome measure, Change From Baseline in Pain on the 11-point Short Pain Scale (SPS-11) at Week 24. Continuous data can take any value on a continuum for a given assessment (for example, a physiological range of values for weight or heart rate).

Once you have added data for the primary outcome measure, you will repeat steps 2–8 and complete steps 13–16 to enter discrete data for the secondary outcome measures in the Parallel Study Design Example. Discrete data are based on counts and represented by integer values (for example, numbers of participants classified as either “responder” or “nonresponder” on an assessment).

Click on the **Edit** link next to an outcome measure.

**Outcome Measures Overview**

[Results Section](#) [Add Outcome Measure](#) [Reorder Outcome Measures](#) [Help](#) [Definitions](#) [Show All](#)

**2** Outcome Measure Data is required for at least one primary outcome measure.

**1. Primary Outcome**

[Edit](#) [Delete](#)

<b>Title:</b>	Change From Baseline in Pain on the 11-point Short Pain Scale (SPS-11) at Week 24
<b>Description:</b>	SPS-11 is a validated, self-reported instrument assessing average pain intensity over the past 24 hour period. Possible scores range from 0 (no pain) to 10 (worst possible pain). Change = (Week 24 Score - Baseline Score). <small>If reporting a score on a scale, please include the unabbreviated scale title, the minimum and maximum values, and whether higher scores mean a better or worse outcome.</small>
<b>Time Frame:</b>	Baseline and Week 24

Outcome Measure Data Not Reported

**2. Secondary Outcome**

[Edit](#) [Delete](#)

<b>Title:</b>	Response Rate - 50 Percent or Greater Reduction in Short Pain Scale (SPS-11) Score
<b>Description:</b>	The response rate was defined as the number of participants with a 50% or greater reduction in SPS-11 pain score from baseline to endpoint. SPS-11 is a validated, self-reported instrument assessing average pain intensity over the past 24 hour period. Possible scores range from 0 (no pain) to 10 (worst possible pain). <small>If reporting a score on a scale, please include the unabbreviated scale title, the minimum and maximum values, and whether higher scores mean a better or worse outcome.</small>
<b>Time Frame:</b>	12 weeks

Outcome Measure Data Not Reported

### Step 3

Review the Outcome Measure Type, Outcome Measure Title, Outcome Measure Description, and Outcome Measure Time Frame fields, which have been prefilled using outcome measure information entered in the Protocol Section previously. Update the information if necessary. Then click on the **Validate** button to check for system validation messages that should be addressed. Address any error messages, and review any warnings or notes carefully and address them if necessary.

### Step 4


Click on the **Enter Outcome Measure Data** button to begin entering data. This action will save any edits you made in step 3.

**Edit Outcome Measure Title Fields**

[Help](#)   [Definitions](#)

* Outcome Measure Type:	Primary
* Outcome Measure Title:	Change From Baseline in Pain on the 11-point Short Pain Scale (SPS-11) at Week 24
[*] Outcome Measure Description:	SPS-11 is a validated, self-reported instrument assessing average pain intensity over the past 24 hour period. Possible scores range from 0 (no pain) to 10 (worst possible pain). Change = (Week 24 Score - Baseline Score).
* Outcome Measure Time Frame:	Baseline and Week 24

[Save](#)   [Validate](#)   [Cancel](#)   [Enter Outcome Measure Data](#)



### Step 5

Click on the **Select** button for the Copy from: Participant Flow option to copy arms/groups from the Participant Flow module.

#### Select Outcome Measure Arms/Groups

Outcome Measure Title: Change From Baseline in Pain on the 11-point Short Pain Scale (SPS-11) at Week 24

Time Frame: Baseline and Week 24

Description: SPS-11 is a validated, self-reported instrument assessing average pain intensity over the past 24 hour period. Possible scores range from 0 (no pain) to 10 (worst possible pain). Change = (Week 24 Score - Baseline Score).

Before entering Outcome Measure data, use a Select button to define the Arms/Groups in your study. You can edit the information on the next screens.

[Help](#) [Definitions](#)

Copy from: <b>Participant Flow</b> <input type="button" value="Select"/>		Arm/Group	Arm/Group
	Title	Remuverol	Placebo
	Description	Participants received Remuverol 15 mg tablet orally twice daily for 24...	Participants received Remuverol placebo tablet matching Remuverol...

5

Create: <b>New</b> <input type="button" value="Select"/>	Define New Arms/Groups
---	------------------------

### Step 6

Review the Arm/Group Information (no edits should be needed), then click on the **Save** button.

**Edit Outcome Measure Arms/Groups**

Arms/Groups copied from: Protocol Section

[+ Add Arm/Group](#)   [Help](#)   [Definitions](#)

\* Arm/Group Title:

\* § Arm/Group Description:

Characters remaining: 91	Characters remaining: 93
Remuverol	Placebo
<p>Characters remaining: 1388</p> <p>Participants received Remuverol 15 mg tablet orally twice daily for 24 weeks.</p> <p>Remuverol: Remuverol 15 mg tablet</p>	<p>Characters remaining: 1367</p> <p>Participants received Remuverol placebo tablet matching Remuverol orally twice daily for 24 weeks.</p> <p>Placebo: Remuverol placebo tablet</p>
<a href="#">x Delete</a>	<a href="#">Move ▶</a>
<a href="#">x Delete</a>	<a href="#">◀ Move</a>

**6**

[Save](#)   [Cancel](#)

\* Required

\* § Required if Primary Completion Date is on or after January 18, 2017

[\*] Conditionally required (see Definitions)

### Step 7

Use the Parallel Study Design Example: Figures and Tables document to determine the numbers of participants analyzed for the outcome measure for each arm/group, as well as any information about how the population was chosen (see tables 2 and 3; relevant text highlighted in yellow below).

**Table 2: Primary Outcome - Change from Baseline to Week 24 in SPS-11 24-Hour Pain Score**

SPS-11 is a validated, self-reported instrument assessing average pain intensity over the past 24 hour period. Possible scores range from 0 (no pain) to 10 (worst possible pain). Change = (Week 24 Score – Baseline Score). Analysis was done on the Intent to Treat Population (all participants assigned to Remuverol or Placebo) with Last observation carried forward (LOCF) imputation method.

MEASURE	REMUVEROL		PLACEBO		DIFFERENCE IN MEANS (SD)*	P VALUE**
	N	MEAN CHANGE (SD)	N	MEAN CHANGE (SD)		
Change in SPS-11 Score	101	-3.84 ± 0.61	99	-2.08 ± 0.51	-1.76 (0.80)	0.002

\*Treatment Difference = Remuverol – Placebo

\*\* Mixed Models Analysis: it was calculated that 200 participants randomized in a 1:1 fashion between the 2 arms would have at least 85% power to detect a difference of 0.56 points in mean SPS-11 pain score between Remuverol and placebo from baseline to week 24. Sample size was determined using a 2-sided 2-sample t test ( $\alpha = 0.05$ ). Assumptions included a common standard deviation of 1.14 and a discontinuation rate of 7%.

**Table 3: Secondary Outcomes - SPS-11 Pain Response Rates from Baseline to Endpoint**

The response rate was defined as the number of participants with a reduction in SPS-11 pain score greater than or equal to the noted level (i.e., 50% or 75%) from baseline to endpoint.

Analysis was based on the per-protocol population (all participants with baseline and week 12 or 24 pain scores available).

TIME FRAME	REMUVEROL		PLACEBO		P VALUE*
	N	NO. RESPONDENTS	N	NO. RESPONDENTS	
RESPONSE RATE AT 50% REDUCTION IN SPS-11 PAIN					
Week 12	98	45	95	37	0.383
Week 24	76	73	81	67	0.009
RESPONSE RATE AT 75% REDUCTION IN SPS-11 PAIN					
Week 24	76	57	81	43	0.005

\* Fisher Exact

Enter the Overall Number of Participants Analyzed for each arm/group.

### Step 8

Enter the Analysis Population Description.

- Primary Outcome, Change From Baseline in Pain on the 11-point Short Pain Scale (SPS-11) at Week 24: The relevant information is highlighted in yellow in the table 2 legend. Enter this information and proceed to step 9.
- Secondary Outcome, Response Rate - 50 Percent or Greater Reduction in Short Pain Scale (SPS-11) Score (Time Frame: 12 Weeks): The relevant information pertains to participants with baseline and week 12 pain scores and is highlighted in yellow in the table 3 legend. Enter this information (for example, “Per-protocol population (all participants with baseline and week 12 pain scores available)”) and advance to step 13.
- Secondary Outcome, Response Rate - 50 Percent or Greater Reduction in Short Pain Scale (SPS-11) Score (Time Frame: 24 Weeks) and Response Rate – 75 Percent or Greater Reduction in Short Pain Scale (SPS-11) Score (Time Frame: 24 Weeks): The relevant information pertains to participants with baseline and week 24 pain scores and is highlighted in yellow in the table 3 legend. Enter this information (for example, “Per-protocol population (all participants with baseline and week 24 pain scores available)”) and advance to step 13.

#### Arms/Groups (2)

	<b>Remuverol</b>	<b>Placebo</b>
* Arm/Group Title:	Remuverol	Placebo
* \$ Arm/Group Description:	Participants received Remuverol 15 mg tablet orally twice daily for 24 weeks. ...	Participants received Remuverol placebo tablet matching Remuverol orally twice d...
* Overall Number of Participants Analyzed:	101	99
+ Add Units Analyzed:	(Optional) Use only if analysis is based on units other than participants (e.g., eyes, lesion ...).	
[*] Analysis Population Description:	Intent to treat population (all participants assigned to Remuverol or Placebo). Last observation carried forward (LOCF) imputation method.	

### Step 9

Locate the Measure Type, Measure of Dispersion/Precision, and data for the primary outcome measure in the Parallel Study Design Example: Figures and Tables document (see table 2; relevant text highlighted in yellow below).



**Table 2: Primary Outcome - Change from Baseline to Week 24 in SPS-11 24-Hour Pain Score**

SPS-11 is a validated, self-reported instrument assessing average pain intensity over the past 24 hour period. Possible scores range from 0 (no pain) to 10 (worst possible pain). Change = (Week 24 Score – Baseline Score). Analysis was done on the Intent to Treat Population (all participants assigned to Remuverol or Placebo) with Last observation carried forward (LOCF) imputation method.

MEASURE	REMUVEROL		PLACEBO		DIFFERENCE IN MEANS (SD)*	P VALUE**
	N	MEAN CHANGE (SD)	N	MEAN CHANGE (SD)		
Change in SPS-11 Score	101	-3.84 ± 0.61	99	-2.08 ± 0.51	-1.76 (0.80)	0.002

\*Treatment Difference = Remuverol – Placebo

\*\* Mixed Models Analysis: it was calculated that 200 participants randomized in a 1:1 fashion between the 2 arms would have at least 85% power to detect a difference of 0.56 points in mean SPS-11 pain score between Remuverol and placebo from baseline to week 24. Sample size was determined using a 2-sided 2-sample t test ( $\alpha = 0.05$ ). Assumptions included a common standard deviation of 1.14 and a discontinuation rate of 7%.

Select “Mean” as the Measure Type and “Standard Deviation” as the Measure of Dispersion/Precision.

## Step 10

Enter the summary-level data for each arm/group.

## Step 11

Enter the Unit of Measure by clicking on the button for the appropriate Commonly reported units, in this case **units on a scale**.

## Step 12

Before leaving the Outcome Measure Data page, click on the **Validate** button to check for system validation messages that should be addressed. Address any error messages, and review any warnings or notes carefully and address them if necessary. Then click on the **Save** button to save your work and return to the Outcome Measures Overview page.

Enter information for the remaining outcome measures by repeating steps 2–8 and then advancing to steps 13–16 to enter discrete data (data reported as counts).



**Outcome Measure Data Table**

\* Measure Type:  9

\* Measure of Dispersion/Precision:  9

	Remuverol	Placebo
Mean	<input type="text" value="-3.84"/> 10	<input type="text" value="-2.08"/>
Standard Deviation	<input type="text" value="0.61"/> 10	<input type="text" value="0.51"/>

+ Add Row

\* Unit of Measure:  11

Commonly reported units:      12

When reporting a scale or score, the Unit of Measure is typically "units on a scale" or "score on a scale".

\* Required

\* § Required if Primary Completion Date is on or after January 18, 2017

[\*] Conditionally required (see Definitions)

## Step 13

The images for steps 13–16 show data entry for the secondary outcome measure Response Rate - 50 Percent or Greater Reduction in Short Pain Scale (SPS-11) Score (Time Frame: 12 Weeks). Once you have added data for this secondary outcome measure, you will repeat steps 2–8 and 13–16 to continue entering data for the remaining secondary outcome measures in the Parallel Study Design Example.

Locate the data for the secondary outcome measures in the Parallel Study Design Example: Figures and Tables document (see table 3; relevant text highlighted in yellow below).

**Table 3: Secondary Outcomes - SPS-11 Pain Response Rates from Baseline to Endpoint**

The response rate was defined as the number of participants with a reduction in SPS-11 pain score greater than or equal to the noted level (i.e., 50% or 75%) from baseline to endpoint. Analysis was based on the per-protocol population (all participants with baseline and week 12 or 24 pain scores available).

TIME FRAME	REMUVEROL		PLACEBO		P VALUE*
	N	NO. RESPONDENTS	N	NO. RESPONDENTS	
RESPONSE RATE AT 50% REDUCTION IN SPS-11 PAIN					
Week 12	98	45	95	37	0.383
Week 24	76	73	81	67	0.009
RESPONSE RATE AT 75% REDUCTION IN SPS-11 PAIN					
Week 24	76	57	81	43	0.005

\* Fisher Exact

Select “Count of Participants” as the Measure Type. “Not Applicable” will automatically be selected as the Measure of Dispersion/Precision. Note: The “Count of Participants” Measure Type is applicable to all three secondary outcome measures.

### Step 14

Enter the data for each arm/group.

### Step 15

“Participants” will appear automatically as the Unit of Measure if “Count of Participants” is selected as the Measure Type.

### Step 16

Before leaving the Outcome Measure Data page, click on the **Validate** button to check for system validation messages that should be addressed. Address any error messages, and review any warnings or notes carefully and address them if necessary. Then click on the **Save** button to save your work and return to the Outcome Measures Overview page.

Enter information for the remaining outcome measures by repeating steps 2–8 and 13–16.

#### Outcome Measure Data Table

* Measure Type:	Count of Participants		Hide calculated percentage
* Measure of Dispersion/Precision:	Not Applicable		
	Remuverol	Placebo	
Number Analyzed	101 participants	99 participants	
Count of Participants	45 44.55%	37 37.37%	
+ Add Category			
+ Add Row			
* Unit of Measure:	participants		

Save

Validate

Cancel

\* Required

\* § Required if Primary Completion Date is on or after January 18, 2017

[\*] Conditionally required (see Definitions)

### Step 17

The images for steps 17–25 show the entry of statistical data for the primary outcome measure, Change From Baseline in Pain on the 11-point Short Pain Scale (SPS-11) at Week 24. Once you have added data for the primary outcome measure, you will repeat steps 17–21 and 25 to enter statistical data for the secondary outcome measures in the Parallel Study Design Example.

Click on the **Add Statistical Analysis 1** link for an outcome measure.

**Outcome Measures Overview**

[Results Section](#)
[Add Outcome Measure](#)
[Reorder Outcome Measures](#)
[Help](#)
[Definitions](#)
[Show All](#)

1. Primary Outcome

[Edit](#)  
  
[Delete](#)  
  
[Copy](#)

Title:	Change From Baseline in Pain on the 11-point Short Pain Scale (SPS-11) at Week 24	
► Description:	SPS-11 is a validated, self-reported instrument assessing average pain... <small>If reporting a score on a scale, please include the unabbreviated scale title, the minimum and maximum values, and whether higher scores mean a better or worse outcome.</small>	
Time Frame:	Baseline and Week 24	

▼ Outcome Measure Data ✓

► Analysis Population Description

Arm/Group Title	Remuverol	Placebo
► Arm/Group Description:	Participants received Remuverol 15 ...	Participants received Remuverol pla...
Overall Number of Participants Analyzed	101	99
Mean (Standard Deviation) <small>Unit of Measure: units on a scale</small>	-3.84 (0.61)	-2.08 (0.51)

[Add Statistical Analysis 1](#)

### Step 18

Locate the statistical data for the primary and secondary outcome measures in the Parallel Study Design Example: Figures and Tables document (see tables 2 and 3; relevant text highlighted in yellow below). Information in these tables will be used to populate the statistical analysis tables as you progress through steps 19–25.

**Table 2: Primary Outcome - Change from Baseline to Week 24 in SPS-11 24-Hour Pain Score**

SPS-11 is a validated, self-reported instrument assessing average pain intensity over the past 24 hour period. Possible scores range from 0 (no pain) to 10 (worst possible pain). Change = (Week 24 Score – Baseline Score). Analysis was done on the Intent to Treat Population (all participants assigned to Remuverol or Placebo) with Last observation carried forward (LOCF) imputation method.

MEASURE	REMUVEROL		PLACEBO		DIFFERENCE IN MEANS (SD)*	P VALUE**
	N	MEAN CHANGE (SD)	N	MEAN CHANGE (SD)		
Change in SPS-11 Score	101	-3.84 ± 0.61	99	-2.08 ± 0.51	-1.76 (0.80)	0.002

\*Treatment Difference = Remuverol – Placebo

\*\* Mixed Models Analysis: it was calculated that 200 participants randomized in a 1:1 fashion between the 2 arms would have at least 85% power to detect a difference of 0.56 points in mean SPS-11 pain score between Remuverol and placebo from baseline to week 24. Sample size was determined using a 2-sided 2-sample t test ( $\alpha = 0.05$ ). Assumptions included a common standard deviation of 1.14 and a discontinuation rate of 7%.

**Table 3: Secondary Outcomes - SPS-11 Pain Response Rates from Baseline to Endpoint**

The response rate was defined as the number of participants with a reduction in SPS-11 pain score greater than or equal to the noted level (i.e., 50% or 75%) from baseline to endpoint. Analysis was based on the per-protocol population (all participants with baseline and week 12 or 24 pain scores available).

TIME FRAME	REMUVEROL		PLACEBO		P VALUE*
	N	NO. RESPONDENTS	N	NO. RESPONDENTS	
RESPONSE RATE AT 50% REDUCTION IN SPS-11 PAIN					
Week 12	98	45	95	37	0.383
Week 24	76	73	81	67	0.009
RESPONSE RATE AT 75% REDUCTION IN SPS-11 PAIN					
Week 24	76	57	81	43	0.005

\* Fisher Exact

Select the outcome measure arms/groups involved in the statistical analysis by marking the Comparison Group Selection checkboxes for the Remuverol and Placebo arms/groups. Use the Comments text field to provide details about the analysis, if available.

- Primary Outcome, Change From Baseline in Pain on the 11-point Short Pain Scale (SPS-11) at Week 24: Enter the information highlighted in the second footnote for table 2. This information details the power (sample size) calculation.
- Secondary Outcomes: No additional information is available.

### Step 19

Select “Superiority” as the Type of Statistical Test used. (Other options are “Non-inferiority,” “Equivalence,” and “Other.”) “Superiority” is chosen for the statistical analyses in this study because an active drug (Remuverol) is compared to an inactive drug (Placebo) with the goal of demonstrating that the active drug is more effective.

#### Statistical Analysis Overview

[Help](#)
[Definitions](#)

<p>* Comparison Group Selection:</p>	<p>Select the Outcome Measure Arms/Groups involved in the statistical analysis.</p> <div style="display: flex; justify-content: space-around;"> <input checked="" type="checkbox"/> Remuverol             <input checked="" type="checkbox"/> Placebo           </div>
<p>Comments:</p>	<p>(Optional) Additional details about the statistical analysis, such as null hypothesis and description of power calculation.</p> <div style="border: 1px solid #ccc; padding: 5px; margin-top: 10px;"> <p style="text-align: right; font-size: 0.8em;">Characters remaining: 103</p> <p>It was calculated that 200 participants randomized in a 1:1 fashion between the 2 arms would have at least 85% power to detect a difference of 0.56 points in mean SPS-11 pain score between Remuverol and placebo from baseline to week 24. Sample size was determined using a 2-sided 2-sample t test (<math>\alpha = 0.05</math>). Assumptions included a common standard deviation of 1.14 and a discontinuation rate of 7%.</p> </div>
<p>* Type of Statistical Test</p>	<div style="display: flex; align-items: center;"> <div style="border: 1px solid #ccc; padding: 2px 5px; margin-right: 5px;">Superiority</div> <div style="border: 2px solid #0056b3; border-radius: 50%; width: 40px; height: 40px; display: flex; align-items: center; justify-content: center; margin-left: 10px; font-size: 1.5em; font-weight: bold;">19</div> </div>
<p>[*] Comments:</p>	<p>If a non-inferiority or equivalence analysis, information on the definition of the non-inferiority or equivalence margin is required. Also describe any other key parameters and details of the power calculation (if not described elsewhere).</p> <div style="border: 1px solid #ccc; height: 40px; margin-top: 10px;"></div> <p style="text-align: right; font-size: 0.8em;">Characters remaining: 500</p>

### Step 20

Enter the calculated P-Value. Use the Comments text field to provide additional information about the p-value, such as the a priori threshold for statistical significance. For the primary outcome measure, the p-value threshold is equivalent to the alpha value used for determining the sample size.

### Step 21

Select the Method used to calculate the P-Value.

- Primary Outcome, Change From Baseline in Pain on the 11-point Short Pain Scale (SPS-11) at Week 24: Select “Mixed Models Analysis” and proceed to step 22.
- Secondary Outcomes: Select “Fisher Exact” and advance to step 25.

### Statistical Test of Hypothesis

[Help](#) [Definitions](#)

<b>[*] P-Value:</b>	(If applicable) <input type="text" value="0.002"/> (e.g. <0.01) <b>20</b>
<b>Comments:</b>	(Optional) Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the <i>a priori</i> threshold for statistical significance. <div>Characters remaining: 194</div> <div>The threshold for statistical significance was p = 0.05.</div>
<b>[*] Method:</b>	(Required if a P-Value is entered) <b>21</b> <div>Mixed Models Analysis ▾ If other, please specify: <input type="text"/></div>
<b>Comments:</b>	(Optional) Any other relevant information, such as adjustments or degrees of freedom. <div>Characters remaining: 150</div> <div></div>

### Step 22

For the primary outcome measure, select “Mean Difference (Net)” as the Estimation Parameter and enter the Estimated Value. The net mean difference compares the difference in the change values (that is, week 24 score minus baseline score for Remuverol vs. week 24 score minus baseline score for Placebo).

### Step 23

For the primary outcome measure, select “Standard Deviation” as the Parameter Dispersion Type and enter the Dispersion Value.

### Step 24

For the primary outcome measure, enter the information highlighted in the first footnote for table 2 in the Estimation Comments text field. This information clarifies the direction of the comparison.

### Step 25

Before leaving the Edit Outcome Statistical Analysis page, click on the **Validate** button to check for system validation messages that should be addressed. Address any error messages, and review any warnings or notes carefully and address them if necessary. Then click on the **Save** button to save your work and return to the Outcome Measures Overview page.

## Outcome Measures Data Entry Walkthrough

### Method of Estimation

[Help](#) [Definitions](#)

**22**

**Estimation Parameter:** (If applicable)  
Mean Difference (Net)  If other, please specify:

**Estimated Value:** Provide the data for the Estimation Parameter.

**Confidence Interval:** (If applicable) [?](#)  
 % Confidence Interval  
Number of sides: 2-Sided   
Lower Limit:   
Upper Limit:

**Parameter Dispersion Type and Dispersion Value:** (If applicable) **23**  
Standard Deviation

**Estimation Comments:** (Optional) Any other relevant estimation information, including the direction of the comparison (e.g., describe which arm or comparison group represents the numerator and denominator for relative risk).  
Treatment Difference = Remuverol - Placebo  
Characters remaining: 208

**24**

### Other Statistical Analysis

[Help](#) [Definitions](#)

**25**

If the statistical analysis cannot be submitted using the Statistical Test of Hypothesis or Method of Estimation options, provide a description and the results of the scientifically appropriate test of statistical significance.  
Characters remaining: 999

Save

Validate

Cancel

\* Required

\* § Required if Primary Completion Date is on or after January 18, 2017

[?](#) Conditionally required (see Definitions)

Enter statistical information for the secondary outcome measures by repeating steps 17–21 and then advancing to step 25.

Return to the Results Section page by clicking on the **Results Section** link at the top of the Outcome Measures Overview page.